Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on November 26, 2018 in Immunotherapy
Learning how to activate and harness the immune system—the body’s built-in defense against disease—has brought the field of oncology to the cusp of a cure for at least some, if not many, types of cancer, according to an international authority in immuno-oncology.
Web Exclusives published on November 26, 2018 in Drug Therapies
New cancer therapies have significantly improved survival outcomes, but have brought with them a wide range of oral toxicities, many of which are class-specific and otherwise new to the field of oncology, according to Nathaniel S. Treister, DMD, DMSc, Division Chief, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA.
Web Exclusives published on November 20, 2018 in Emerging Therapies
Chicago, IL—A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a pre­liminary phase 1b clinical trial. The addition of CMP-001 to pembrolizu­mab was well-tolerated, with encouraging antitumor responses in patients with metastatic melanoma that progressed with or after treatment with a PD-1 inhibitor.
Web Exclusives published on November 13, 2018 in FDA Approvals
In August, the FDA approved lenvatinib for the first-line treatment of patients with unresectable hepatocellular carcinoma, based on the results of the REFLECT clinical trial.
Web Exclusives published on November 13, 2018 in Immunotherapy
“This study is a fantastic advance for patients with brain metastases. It shows that combination immunotherapy can shrink brain metastases in a substantial proportion of patients,” said Michael A. Postow, MD.
Web Exclusives published on October 22, 2018 in Immunotherapy
“The overall survival findings are far superior to what we might anticipate with traditional therapies in this relapsed or refractory DLBCL population,” said Jeremy S. Abramson, MD, MMSc.
Web Exclusives published on October 22, 2018 in Breast Cancer
Analysis of a phase 3 clinical trial showed that 6 months of trastuzumab was noninferior to 12 months in terms of disease-free survival, and was also associated with a 50% reduction in cardiotoxicity.
Web Exclusives published on October 16, 2018 in Immunotherapy
At ASCO 2018, 3 new studies that explore chemotherapy plus immunotherapy got high remarks from Sibylle Loibl, MD, PhD, including a regimen that may be a new standard of care.
Web Exclusives published on October 16, 2018 in Lynch Syndrome
The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.
Web Exclusives published on October 15, 2018 in Breast Cancer

The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.

Page 4 of 13
Results 31 - 40 of 122